Skip to content
Triangle logo TriangleGet started
← Myelodysplastic Syndromes

NCT00053989 · STUDY IN CONTEXT

NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders

Draft scope assessment: narrower. Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. The condition was transformed or resolved through the terminology hierarchy to reach this cancer type, so the link itself is a candidate a reviewer must confirm. Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.

Read the full study record and all posted results →

Linked outcomes

Measures are not ranked. Open each original source section for treatment groups, denominators, units and results.

primary · POSTED

treatment related mortality within 100 days from hematopoietic stem cell (HSC) infusion on day 0

Source null

→

primary · POSTED

Best disease response measured within 100 days from hematopoietic stem cell (HSC) infusion on day 0 using disease specific response criteria defined in the protocol

Source null

→

secondary · POSTED

Progression free survival defined as time from HSC infusion (day 0) until progression of disease or death due to any cause. Patients are censored if alive without disease progression through 1 year after HSC infusion

Source null

→

secondary · POSTED

Overall survival with events defined as death due to any cause and censored patients are alive as of 1 year post HSC infusion

Source null

→

secondary · POSTED

overall grade II-IV acute GvHD

2 participants died before they were eligible for this outcome

→

Reported safety

Serious events are not the same as severe events. Compare the original safety groups and their at-risk populations.

Open the study safety table →

Quality of life and patient-reported measures

No linked quality-of-life measure is recorded for this setting and study.

Full draft applicability and source-link record
trial
release id
clinical-indications-draft-1
disease state id
ds-myelodysplastic-syndromes
nct id
NCT00053989
trial label
NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders
applicability
narrower
applicability note
Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. The condition was transformed or resolved through the terminology hierarchy to reach this cancer type, so the link itself is a candidate a reviewer must confirm.
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
provenance class
registry-condition-search
discovery note
Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
outcome Count
5
harms Count
1
qol Count
0
outcomes
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-myelodysplastic-syndromes
    nct id
    NCT00053989
    outcome key
    om-0000
    source section id
    NCT00053989-om-0000
    source outcome index
    0
    endpoint
    Day 100 TRM
    endpoint definition
    treatment related mortality within 100 days from hematopoietic stem cell (HSC) infusion on day 0
    time origin
    from start or conditioning (day -6 or -5) through day +100 after HSC infusion
    analysis role
    primary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  2. release id
    clinical-indications-draft-1
    disease state id
    ds-myelodysplastic-syndromes
    nct id
    NCT00053989
    outcome key
    om-0001
    source section id
    NCT00053989-om-0001
    source outcome index
    1
    endpoint
    Day 100 Best Response
    endpoint definition
    Best disease response measured within 100 days from hematopoietic stem cell (HSC) infusion on day 0 using disease specific response criteria defined in the protocol
    time origin
    from start of conditioning on day -6 or -5 through day +100 after HSC infusion
    analysis role
    primary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  3. release id
    clinical-indications-draft-1
    disease state id
    ds-myelodysplastic-syndromes
    nct id
    NCT00053989
    outcome key
    om-0002
    source section id
    NCT00053989-om-0002
    source outcome index
    2
    endpoint
    PFS
    endpoint definition
    Progression free survival defined as time from HSC infusion (day 0) until progression of disease or death due to any cause. Patients are censored if alive without disease progression through 1 year after HSC infusion
    time origin
    1 year
    analysis role
    secondary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  4. release id
    clinical-indications-draft-1
    disease state id
    ds-myelodysplastic-syndromes
    nct id
    NCT00053989
    outcome key
    om-0003
    source section id
    NCT00053989-om-0003
    source outcome index
    3
    endpoint
    OS
    endpoint definition
    Overall survival with events defined as death due to any cause and censored patients are alive as of 1 year post HSC infusion
    time origin
    1 year
    analysis role
    secondary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  5. release id
    clinical-indications-draft-1
    disease state id
    ds-myelodysplastic-syndromes
    nct id
    NCT00053989
    outcome key
    om-0004
    source section id
    NCT00053989-om-0004
    source outcome index
    4
    endpoint
    Acute GvHD
    endpoint definition
    overall grade II-IV acute GvHD
    time origin
    Day +100
    analysis role
    secondary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    2 participants died before they were eligible for this outcome
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
arms
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-myelodysplastic-syndromes
    nct id
    NCT00053989
    outcome key
    om-0000
    arm key
    OG000
    arm label
    All Patients
    regimen
    All patients enrolled on study
    analyzed count
    41
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT00053989-om-0000#groups/OG000
  2. release id
    clinical-indications-draft-1
    disease state id
    ds-myelodysplastic-syndromes
    nct id
    NCT00053989
    outcome key
    om-0001
    arm key
    OG000
    arm label
    All Patients
    regimen
    All patients enrolled on study
    analyzed count
    41
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT00053989-om-0001#groups/OG000
  3. release id
    clinical-indications-draft-1
    disease state id
    ds-myelodysplastic-syndromes
    nct id
    NCT00053989
    outcome key
    om-0002
    arm key
    OG000
    arm label
    All Patients
    regimen
    All patients enrolled on study
    analyzed count
    41
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT00053989-om-0002#groups/OG000
  4. release id
    clinical-indications-draft-1
    disease state id
    ds-myelodysplastic-syndromes
    nct id
    NCT00053989
    outcome key
    om-0003
    arm key
    OG000
    arm label
    All Patients
    regimen
    All patients enrolled on study
    analyzed count
    41
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT00053989-om-0003#groups/OG000
  5. release id
    clinical-indications-draft-1
    disease state id
    ds-myelodysplastic-syndromes
    nct id
    NCT00053989
    outcome key
    om-0004
    arm key
    OG000
    arm label
    All Patients
    regimen
    All patients enrolled on study
    analyzed count
    39
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT00053989-om-0004#groups/OG000
harms
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-myelodysplastic-syndromes
    nct id
    NCT00053989
    harm key
    EG000
    source section id
    NCT00053989-ae
    event group key
    EG000
    event group label
    All Patients
    serious affected
    3
    serious at risk
    41
    other affected
    6
    other at risk
    41
    frequency threshold
    0
    collection period
    100 days
    event definition
    SAE=died before absolute neutrophil count recovery (DBE) or survived to day +28 without absolute neutrophil count recovery (FTE) AE=overall grade III-IV acute GVHD
    undenominated note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
quality of life
    setting source links

      Preserved source evidence · Not medical advice